NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial

NCT07077551 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

28

Enrollment

OTHER

Sponsor class

Conditions

NENS

Interventions

DRUG: NALIRIFOX

Sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University